Skip to main content
Equibles
ENGN logo

ENGN · enGene Therapeutics Inc. · Metrics

Track ENGN — free

Use ENGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ENGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.67 +0.09 (+5.70%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — cleared Jun 15, 2026

The latest filing states the doubt was alleviated.

“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”
View the 10-Q filed Jun 15, 2026
Market Cap
$111.92M
Shares
67.02M
Volume · Oct 20 1.12M Avg daily vol (3M) 741.53K

ENGN metrics

73 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.67
Market cap
$111.92M

Price action

20 metrics
Price change (1W)
-7.1%
Price change (30D)
-19.4%
Price change (3M)
-15.5%
Price change (6M)
-81.5%
Price change (YTD)
-82.5%
Price change (1Y)
-83.1%
Trailing year
Price change (5Y)
—
52-week high
$12.17
52-week low
$1.44
Change from 52-week high
-87.0%
Change from 52-week low
+9.7%
Annualized volatility
118.3%
Annualized volatility (3M)
50.8%
Beta
2.1
RSI (14D)
35.8
Price vs SMA 50
-13.6%
Price vs SMA 200
-66.3%
Avg volume (3M)
735,960
Relative volume
1.1
Average dollar volume
$1.35M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
67.02M

Valuation

12 metrics
P / E (TTM)
0.7
Trailing earnings · reciprocal yield 153.8%
PEG ratio
0.0
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.5
reciprocal yield 217.5%
FCF yield
-98.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-123.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$136.65M
Net income (TTM)
−$130.36M
Trailing 12 months
Diluted EPS (TTM)
$2.43
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.18
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-2.08
Operating cash flow per diluted share (TTM)
$-1.62
Free cash flow per diluted share (TTM)
$-1.64
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$1.55
Stock compensation per diluted share (TTM)
$0.26
Book value per share
$3.22

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
+56.8%
Shares change YoY
+36.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
-62.7%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-56.6%
Return on assets
-45.2%
Debt / equity
0.1
Current ratio
10.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$104.00M
Quick ratio
10.2
Interest coverage
-44.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$240.97M
Latest balance sheet
Cash & equivalents
$41.02M
Total assets
$288.32M
Total debt
$25.35M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$103.31M
Capital expenditures (TTM)
$688,000
R&D (TTM)
$96.26M
SG&A (TTM)
—
Stock compensation (TTM)
$17.36M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
70
13F filer change QoQ
+8
Institutional ownership
79.2%
Conviction holders (share of 13F filers)
5.0%
Crowding (high-turnover and private-fund holders)
41.5%
Private-fund adviser ownership
39.8%
Active holders' share change QoQ
-10.9%
Holder tenure
4.6
Price vs estimated holder cost
-72.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.1%

Short interest

3 metrics
Short interest
2.1%
Latest settlement · 1.8 days to cover
Days to cover
1.8d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
$10,051
Insider-sentiment score
75 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1980845 CUSIP 29286X101 13F (30d) 2 filings 2 filers Visit website Investor relations